MOH
- Marketing authorisation holder: SYNDAX
- Status: likely_approved
Revuforj (REVUMENIB) regulatory status in United Arab Emirates.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH has authorised it.
SYNDAX holds the UAE marketing authorisation.